Moderna

Today we announced data regarding two of our investigational influenza candidates will be presented at IDWeek 2025, October 19-22, 2025, in Atlanta, GA. Read more: https://lnkd.in/eS3kf5YZ

Today we announced that clinical, safety and translational data from our Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma patients will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025, in Berlin, Germany.   Read more: https://lnkd.in/eJUhVv4s

We were honored to be named Vizient, Inc’s 2025 Pharmaceutical Supplier Partner of the Year at the #VizientAwards. This award reflects our shared commitment to advancing innovation and delivering meaningful impact for patients. Thank you, Vizient, for this recognition and your continued partnership. Read more: https://lnkd.in/g7Mcfnqu

Today we announced that the Moderna Innovation and Technology Centre (MITC) at the Harwell Science and Innovation Campus in Oxfordshire, UK has officially opened. The MITC will now produce British-made mRNA respiratory vaccines for the UK public to support the National Health Service seasonal vaccination programs.    Learn more: https://lnkd.in/e836M7Rv

Today, on #WorldCancerResearchDay, we reflect on the collective progress made in the fight against cancer and the vital work still ahead. Cancer affects millions of people and families worldwide, reminding us of the urgency to continue advancing research and innovation. We are deeply grateful to the scientists, clinicians, patients and advocates whose dedication drives discovery each day. Together, we move closer to a future with more options and more hope for those impacted by cancer.

Today we announced positive preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE® (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Learn more: https://lnkd.in/ew-JUgCY.

Today we announced that the first mRNA vaccines fully manufactured in Canada are being shipped to Canadian provinces and territories. This milestone advances Canada’s domestic vaccine production capacity and strengthens national health security. Read more: https://lnkd.in/eY-SJsTv.

Today we announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. Learn more: https://lnkd.in/dByZr_s8.

We aspire to be active contributors to the communities where we live and work. Back-to-school season should be about excitement and possibility—not stress over missing supplies. That’s why one of our teams organized a supply drive in partnership with United Way of Tri-County to help students in our local communities start the year confident and prepared. From backpacks to notebooks, crayons to calculators, colleagues came together to provide the essentials kids need to thrive in the classroom.

We are immensely proud of the role we played in the historic achievements of Operation Warp Speed. COVID-19 vaccines helped end the pandemic, re-open economies and save millions of lives. mRNA, the same technology that helped turn the tide of a global pandemic, is now paving the way for breakthroughs in cancer, autoimmune and rare diseases.   To help ensure Americans have clear and accessible information, we will be compiling previously disclosed information here: https://lnkd.in/eMSuchne